Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147770 | 0.83 | CSF1R (0.71) | CSF1R | |
| SCHEMBL14096152 | 0.82 | CSF1R (0.73) | CSF1R | |
| SCHEMBL13405646 | 0.80 | CSF1R (0.75) | CSF1R | |
| SCHEMBL13405645 | 0.79 | CSF1R (1.00) | CSF1R | |
| SCHEMBL13405640 | 0.79 | CSF1R (1.00) | CSF1R | |
| SCHEMBL31157980 | 0.79 | CSF1R (1.00) | CSF1R | |
| SCHEMBL5202289 | 0.79 | CSF1R (1.00) | CSF1R | |
| SCHEMBL14385081 | 0.78 | CSF1R (0.69) | CSF1R | |
| SCHEMBL13405642 | 0.78 | CSF1R (0.81) | CSF1R | |
| SCHEMBL14096401 | 0.78 | CSF1R (1.00) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028587-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | NOVOGLIA, INC. | 2026-01-29 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230081264-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | SAVANNA BIOTHERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028587-A1 | COMPOSITIONS AND METHODS FOR MICROGLIA REPLACEMENT THERAPY | CSF1R, CSF3R, GMFG | CSF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.